Edition:
United Kingdom

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

24.71USD
17 Oct 2018
Change (% chg)

$-0.14 (-0.56%)
Prev Close
$24.85
Open
$24.79
Day's High
$24.79
Day's Low
$24.68
Volume
1,334
Avg. Vol
74,272
52-wk High
$37.45
52-wk Low
$22.25

Latest Key Developments (Source: Significant Developments)

Revance Releases Second Quarter 2018 Results
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Revance Therapeutics Inc ::REVANCE RELEASES SECOND QUARTER 2018 RESULTS.REVANCE THERAPEUTICS - EXPECTS TO COMPLETE SAKURA 3 OPEN-LABEL, LONG-TERM SAFETY STUDY OF RT002 FOR TREATMENT OF GLABELLAR (FROWN) LINES IN Q4.REVANCE THERAPEUTICS - ON TRACK TO FILE BLA FOR RT002 TO TREAT GLABELLAR (FROWN) LINES IN H1 2019.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2018 WERE $233.7 MILLION.REVANCE THERAPEUTICS - REITERATES FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018.Q2 REVENUE $0.7 MILLION VERSUS $0.1 MILLION.REVANCE THERAPEUTICS QTRLY DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.94.Q2 EARNINGS PER SHARE VIEW $-0.94, REVENUE VIEW $514000.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Revance Says Lauren Silvernail Has Resigned As Co's Chief Financial Officer
Tuesday, 29 May 2018 

May 29 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.REVANCE THERAPEUTICS INC -LAUREN SILVERNAIL HAS RESIGNED AS REVANCE'S CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER, EFFECTIVE AS OF MAY 29, 2018.REVANCE THERAPEUTICS INC - REVANCE IS INITIATING A SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.  Full Article

Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS.REVANCE THERAPEUTICS INC - TRIAL'S PRIMARY ENDPOINT SHOWED ROBUST IMPACT ON PAIN, WITH GREATER THAN 50% REDUCTION FOR PATIENTS TREATED WITH RT002.REVANCE THERAPEUTICS INC - RT002 APPEARED TO BE GENERALLY SAFE AND WELL-TOLERATED THROUGH WEEK 8.REVANCE THERAPEUTICS - EXPECT TO CONDUCT ANOTHER PHASE 2A TRIAL WITH MODIFIED DESIGN TO DEMONSTRATE RT002'S ABILITY TO TREAT PLANTAR FASCIITIS.  Full Article

Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Revance Therapeutics Inc ::REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018.REVANCE THERAPEUTICS INC - EXPECTS TO COMPLETE RT002 SAKURA PHASE 3 PROGRAM AND START RT002 PHASE 3 TRIAL FOR CERVICAL DYSTONIA IN 2018.REVANCE THERAPEUTICS INC - EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION.REVANCE THERAPEUTICS INC - ANTICIPATES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE TO BE IN RANGE OF $84 TO $101 MILLION.  Full Article

Revance Announces Pricing Of Public Offering Of Common Stock
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $31.00 PER SHARE​.  Full Article

Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​.  Full Article

Revance Announces Proposed Public Offering Of Common Stock
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK.REVANCE THERAPEUTICS INC - CERTAIN STOCKHOLDERS OF CO ARE ALSO OFFERING 600,000 SHARES OF COMPANY'S COMMON STOCK FOR SALE TO PUBLIC.  Full Article

Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES.SAYS RT002 DELIVERED HIGHLY STATISTICALLY SIGNIFICANT REDUCTION IN SEVERITY OF GLABELLAR LINES AT WEEK 24.SAYS RT002 DELIVERED POSITIVE TOP-LINE RESULTS IN ALLEVIATING MODERATE-TO-SEVERE GLABELLAR LINES IN 2 PIVOTAL SAKURA PHASE 3 TRIALS.SAYS RT002 APPEARED GENERALLY SAFE AND WELL-TOLERATED IN BOTH STUDIES.SAYS ASSUMING SUCCESSFUL COMPLETION OF SAKURA 3, COMPANY PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION IN FIRST HALF OF 2019.SAYS LONG-TERM SAFETY TRIAL, SAKURA 3, IS FULLY ENROLLED AND IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2018.SAYS COMPANY PLANS TO LAUNCH RT002 IN U.S. IN 2020, PENDING APPROVAL BY FDA.  Full Article

Revance Plans Phase 3 Program For RT002 Injectable To Treat Cervical Dystonia
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Revance Therapeutics Inc ::REVANCE PLANS PHASE 3 PROGRAM FOR RT002 INJECTABLE TO TREAT CERVICAL DYSTONIA.REVANCE THERAPEUTICS INC - COMPANY COMPLETES END-OF-PHASE 2 MEETING WITH FDA.REVANCE THERAPEUTICS - FINALIZING TRIAL PROTOCOLS FOR PIVOTAL RT002 PROGRAM, WHICH IS PLANNED TO COMMENCE IN Q2 2018.  Full Article

Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Revance Therapeutics Inc :Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia.Revance Therapeutics Inc - ‍U.S. FDA granted orphan drug designation for Co's product candidate, Daxibotulinumtoxina for injection (RT002)​.  Full Article

Photo

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.